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Background: High-throughput DNA sequencing produces vast amounts of data, with millions of short reads that
usually have to be mapped to a reference genome or newly assembled. Both reference-based mapping and de novo
assembly are computationally intensive, generating large intermediary data files, and thus require bioinformatics skills
that are often lacking in the laboratories producing the data. Moreover, many research and practical applications in
microbiology require only a small fraction of the whole genome data.
Results: We developed KvarQ, a new tool that directly scans fastq files of bacterial genome sequences for known
variants, such as single nucleotide polymorphisms (SNP), bypassing the need of mapping all sequencing reads to a
reference genome and de novo assembly. Instead, KvarQ loads “testsuites” that define specific SNPs or short regions of
interest in a reference genome, and directly synthesizes the relevant results based on the occurrence of these markers
in the fastq files. KvarQ has a versatile command line interface and a graphical user interface. KvarQ currently ships with
two “testsuites” for Mycobacterium tuberculosis, but new “testsuites” for other organisms can easily be created and
distributed. In this article, we demonstrate how KvarQ can be used to successfully detect all main drug resistance
mutations and phylogenetic markers in 880 bacterial whole genome sequences. The average scanning time per
genome sequence was two minutes. The variant calls of a subset of these genomes were validated with a standard
bioinformatics pipeline and revealed >99% congruency.
Conclusion: KvarQ is a user-friendly tool that directly extracts relevant information from fastq files. This enables
researchers and laboratory technicians with limited bioinformatics expertise to scan and analyze raw sequencing data
in a matter of minutes. KvarQ is open-source, and pre-compiled packages with a graphical user interface are available
at http://www.swisstph.ch/kvarq.
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Large-scale whole-genome sequencing (WGS) is revolu-
tionizing microbiology and public health [1-3]. Thanks
to the latest technological advances, bacterial genomes
can now be sequenced in less than 48 hours for less than
€100 per genome. New benchtop devices are providing
WGS capability to routine microbiological laboratories,
and WGS is now becoming an important part of clinical
microbiology and molecular epidemiology. This emerging
field of “genomic epidemiology” [4-11] already comprises* Correspondence: sebastien.gagneux@unibas.ch
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unless otherwise stated.numerous studies that have evaluated the potential of
WGS to trace the transmission of pathogens such as Clos-
tridium difficile, Pseudomonas aeruginosa, Klebsiella
pneumonia, Neisseria meningitidis, Staphylococcus aureus
and Mycobacterium tuberculosis [12-21]. Moreover, WGS
is playing an increasing role in molecular drug susceptibil-
ity testing (DST) and the identification of drug resistance
mutations [22-28]. It is expected that WGS will eventually
replace all other bacterial genotyping methods [29].
In contrast to the increasing availability of WGS platforms,
the capability to analyse WGS data is lagging behind, par-
tially because of the lack of rapid and user-friendly analysis
tools. Extracting single nucleotide polymorphisms (SNPs),
the most widely studied form of genetic variation, from
WGS data requires substantial bioinformatics expertise, asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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based on customized scripts. Moreover, this standard
approach of analysing WGS data is time-consuming
and computationally expensive [30], and as a conse-
quence, biological questions can often not be addressed
directly by the people generating the data. Furthermore,
large amounts of data are produced when analyzing
complete genomes, although often only a small propor-
tion of these data are relevant for the study question;
this is particularly true when screening for drug resist-
ance determinants. Identifying individual SNPs of inter-
est usually requires mapping all sequencing reads in a
fastq file to a given reference genome, despite the fact
that only a few nucleotide positions might be relevant.
Tools have been developed to speed up the extraction of
relevant information. These include in silico multi-locus
sequence typing (MLST) from draft genomes or contigs,
but all these methods rely on previous assembly [31-33].
One of these tools, SRST, facilitates the process by accept-
ing fastq files for a given typing scheme. SRST uses BWA
and SAMtools and is highly configurable, but is aimed at
the bioinformatically skilled users and lacks a graphical
interface. However, a graphical interface is crucial for
making these kinds of genome analyses accessible to a
broader group of microbiologists, including the ones pri-
marily interested in routine clinical applications. Conse-
quently, there is a need for software able to extract allelic
information directly from the raw sequencing reads with-
out the need of previous mapping or de novo assembly.
Here we present KvarQ, a software that enables rapid
screening of short sequence reads for mutations at multiple
nucleotide positions of interest. KvarQ uses as input a fastq
file, and generates the output in form of a text file in Java-
Script Object Notation (json) format. Using a complete
bacterial genome sequence as a reference, KvarQ can inter-
rogate any single nucleotide position or short DNA
sequence of interest for known or unknown mutations,
respectively.
KvarQ is universally applicable to any short read data-
set and corresponding reference sequence, and is highly
adaptable with respect to target polymorphisms. Clinical
microbiological laboratories will benefit from KvarQ’s
short analysis time, while laboratories in resource-limited
settings can get access to genome analysis despite the lack
of advanced computational infrastructure and/or appro-
priately skilled staff.
Even advanced users will save time by avoiding the need
for formal mapping or assembly to answer specific ques-
tions, particularly when studying large numbers of genomes.
KvarQ is available for Linux, OS X and Windows, and
runs on any portable or desktop system. A command
line interface and a simple graphical user interface are
available. We aimed at a self-explaining application with
short run times (<20 minutes on a standard workstationfor a fastq file of 1000 MB), while keeping the program
flexible enough to be used with other organisms. KvarQ
can be downloaded (source code as well as precompiled
packages) from http://www.swisstph.ch/kvarq.
Implementation
Overview
KvarQ analyzes a fastq file and detects the allelic state of
known polymorphisms, and compiles all the relevant in-
formation about the genome sequence. In contrast to
current genetic analysis software [31,33], KvarQ extracts
the relevant information directly from the sequencing
reads, without the need to map every read to a reference
genome. The software can be used via the command line
or the graphical user interface, and is split into one part
that scans the fastq files and saves the results to a json
file, and a second part that extracts and illustrates the
information contained in the json file. Although results
reported in this article mainly use sequencing data from
the Mycobacterium tuberculosis complex (MTBC), the
software can be used with any short read sequencing
data from any organism. Currently, KvarQ is optimized
for haploid organisms, but could be extended to analyze
diploid data sets. In principle, KvarQ could be used to
scan through very large datasets, such as from human
genomes, although the scan time would increase linearly
with data size.
Algorithm and parameters
The following paragraphs describe the information flow
inside KvarQ from the fastq files to the final results that
are displayed to the user (Figure 1).
Before the scanning process, target sequences are gener-
ated from known mutations or regions of interest. KvarQ
uses a modular approach, where different “testsuites” (re-
alized as python modules) define known single nucleotide
polymorphisms (SNPs) or small regions of interest that
harbour potential mutations (such as the Rifampicin
Resistance-Determining Region, RRDR, in MTBC [34]).
The target genomic sequence is extracted from a reference
genome and flanked on both sides with additional bases.
These flanking regions increase the length of the sequence
and thereby increase the coverage over the region of inter-
est (see Figure 2). For each of these “target sequences”, the
corresponding base-sequence on the complementary
strand is also generated.
The actual scanning algorithm is implemented in C and
splits the fastq file into small parts that are distributed to
multiple threads and scanned simultaneously. First, every
read is trimmed by a user-specified minimum quality score.
The trimmed part is then shifted along each of the target
sequences and every match (not exceeding a specified
number of single nucleotide differences) is recorded in the
“hit-list” if a minimum overlap is warranted. Currently, no
Figure 1 Simplified overview of scanning process and preparation. “Testsuites” are python source files that define the SNPs of interest (or in
this case a 3 base pair long region) as well as other relevant genetic information (in this case the katG gene in which mutations can confer
isoniazid resistance). This information is used to extract a “target sequence” from a reference MTBC genome: on both sides, additional bases
(“flanks”) are concatenated to avoid border effects within the sequence of interest. During the scanning process, every read is trimmed
depending on its PHRED score (in this case, a quality cutoff of Q = 13 was defined which corresponds to the ASCII character “/”). After the
scanning, the part of the reads that matched the target sequence and exceeded the minimum quality score (represented with gray bars) are
assembled to a “coverage” that indicates the overall coverage depth as well as all detected mutations (green). In a further step, additional
information is generated from this coverage (such as the resulting amino acid sequence) and finally a short “result” string is generated that
summarizes the result of the scanning process.
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the target sequences. This works fast enough for the short
target sequences used in our analysis. The scanning
process continues until the whole file is scanned or a speci-
fied minimum coverage is reached.
Next, the data gathered from the fastq files is translated
into intermediary data structures (“coverages”). These data
structures combine the reads from the original as well as
the complementary strand, position them within theFigure 2 Interactive inspection of “coverage”. This screenshot shows th
red lines, corresponding to codon 315 in katG) and the surrounding flankin
long sequence (in green, text description at bottom of window). The decre
set to a value equal to the length of the two flanking regions.genome, and summarize non-matching bases in reads
(these can be true mutations in the genome or sequencing
errors).
Finally, the testsuites determine the results based on the
information conveyed by the intermediary data structures
created in the last step. Currently, mutations are extracted
by using a simple threshold that separates them from se-
quencing errors – this is possible because KvarQ neglects
bases that do not satisfy the minimum read qualitye coverage over a short region of interest (3 base pairs within vertical
g sequence. Note the mutation in the middle of the three base pair
ase of coverage on both sides is due to the minimum overlap that is
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tion is processed further varies depending on the various
testsuites. For example, the phylogenetic testsuite we ap-
plied for MTBC uses three phylogenetically informative
SNPs for every lineage and imposes logical constraints on
sublineages. For example, any genome belonging to the
MTBC “Beijing” sublineage must also have the SNPs char-
acteristic of “Lineage 2”. The resistance testsuite checks for
every mutation whether a change in amino acid sequence
follows the nucleotide change (non-synonymous muta-
tions) and only reports those to the user. If the results have
a low confidence due to low coverage of the sequences, this
is also added as a remark to the result output.
Data format and analysis
KvarQ uses fastq files with Solexa, Sanger and different
Illumina quality scores as input files. The quality format
is determined by a heuristic search. Only one input file
per genome sequence is accepted, and paired-end files
are automatically included. The output is structured data
in json format, a human readable file that contains infor-
mation about the scanning process (parameters used,
fastq file size, statistics about read number, length and
quality, and scan time), the final results, and the inter-
mediary data structures that were used to calculate these
results. The information contained in the json file can
be used to re-calculate the results without the need to
re-scan the fastq file, because most of the relevant infor-
mation is contained in the intermediary data structures
that are saved along with the results in the json file.
To facilitate the extraction of relevant results, KvarQ
provides data analysis tools to inspect the data interactively
from the command line or with a hierarchical menu-
driven graphical user interface. The “json explorer” shows
the summarized test results for every testsuite (KvarQ’s
main goal is to be user-friendly) as well as detailedFigure 3 Interactive inspection of json file. The upper pane of each windo
the json file. In the left window, the drug resistance section is selected and th
(the “+” in front of the “Isoniazide resistance” indicates a non-synonymous mu
showing that all SNPs for “lineage 2” and “beijing sublineage” were found.information about the coverage of every target sequence
that was used by the different testsuites (Figures 2 and 3).
The interactive exploration of this wealth of information is
intended for the advanced operator to get, for example, a
better impression of the usefulness of newly designed tar-
get sequences or the fastq quality. Additionally, the “json
explorer” displays overall number of reads in a fastq file
and the length of the reads.
Results
We validated KvarQ with 880 fastq files of predomin-
antly Mycobacterium tuberculosis complex (MTBC) iso-
lates, for which we interrogated 206 genomic positions
where polymorphisms have been previously described
(Additional files 1 and 2).
In MTBC, single nucleotide mutations are reliable drug
resistance markers, as most phenotypic drug resistance is
conferred by single amino acid changes [34-36]. Hence,
molecular DST is becoming increasingly widespread in
the diagnosis of TB, and various genotyping platforms
make use of these markers. Moreover, SNPs are powerful
phylogenetic markers in MTBC, because similar to other
genetically monomorphic bacteria, MTBC exhibits limited
horizontal gene exchange and as a consequence, SNP
homoplasies are rare [37,38]. Hence, SNPs can be used to
study the evolutionary history of MTBC, as well as to clas-
sify clinical strains associated with variable degrees of viru-
lence or different clinical outcomes [39,40]. MTBC
comprises several phylogenetic lineages, and SNPs repre-
sent ideal markers to classify clinical MTBC isolates into
these lineages [41,42].
In this study, we included 27 SNPs as phylogenetic
markers defining MTBC lineages and sublineages, as well
as 32 single nucleotide mutations and three genomic
regions (63 base pairs (bp) in gyrA, 81 bp in rpoB and 3 bp
in katG) associated with drug resistance (Additional file 1).w in these screenshots shows the main categories of data contained in
e lower pane shows details about all target sequences in this testsuite
tation). In the right window, the phylogenetic section is selected,
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whole genome sequences of clinical MTBC isolates and
additionally downloaded sequences from public se-
quence read archives (Additional file 2). Different, over-
lapping subsets of fastq files were used for i) the
comparison of SNP-calls with a standard BWA-based
mapping pipeline (N = 206), ii) detecting drug resistance
mutations (N = 19) and iii) comparison of KvarQ phylo-
genetic classification with laboratory based classification
(N = 321) – see Figure 4. In addition to these well-
characterized genome subsets, we used a previously
published “blind” subset of 388 fastq files downloaded
from a public source to extract phylogenetic information
and drug resistance mutations, which were not reported
in the original publication [21].
KvarQ scanning times and overall performance
First, we applied KvarQ to all 880 fastq files and calcu-
lated scanning times for the set of SNPs described. The
scanning times were found correlated with the average
genome coverage (or the total base output) in the fastq
file. A genome sequence file with 100-fold coverage of
the MTBC genome required approximately 2 minutes of
KvarQ scanning time, and increased linearly with se-
quence coverage (Figure 5).Figure 4 FastQ dataset used to validate KvarQ. A total of 880 whole ge
this study. All 880 genome sequences were scanned for phylogenetic class
overlapping subsets were used to i) compare SNP calls obtained with Kvar
and SAMtools for 206 isolates, ii) compare KvarQ phylogenetic classification
compare KvarQ drug resistance mutations with previously identified drug r
additional information, i.e. phylogenetic classification and drug resistance m
study [21]. More information can be found in Additional file 2.To assess overall performance, we looked at phylogenetic
classifications in all 880 fastq files. These files included
whole genome sequences generated on different sequen-
cing devices using different laboratory procedures (i.e. li-
brary preparations), and of unknown quality (Additional
file 2). Successful phylogenetic classification was obtained
for 865/880 fastq files (98.3%) (Figure 6). The remaining 15
included the chimpanzee bacillus [43], Mycobacterium
canettii and eight confirmed non-MTBC isolates, for all of
which no MTBC lineage classification would be expected.
For five other strains, no MTBC lineage-specific SNP was
detected, which can be due to low coverage or because iso-
lates were not MTBC.
Furthermore, we compared the number of KvarQ hits
per position with overall base output in the fastq file (data
not shown). The correlation varied strongly between posi-
tions on the genomes and between fastq files, which indi-
cates that the number of hits per SNP depends on the SNP
queried (i.e. the particular genomic region being interro-
gated) and the quality of the base calls in the fastq file.
Comparison of SNP-calls with BWA calls
A subset of 206 FastQ files was used to directly compare
SNP-calls obtained with KvarQ with SNP-calls generated
with our standard pipeline using BWA, SAMtools, BCFtoolsnome sequences in FastQ format from various sources were used in
ification and drug resistance mutation identification. Different,
Q with SNP calls of our standard SNP-calling pipeline based on BWA
of 321 MTBC isolates with previous phylogenetic information, iii)
esistance associated mutations in 19 MTBC isolates, and iv) obtain
utations, from a “blind” set of 388 genome sequences from a recent
Figure 5 KvarQ scanning time for all 206 polymorphic
positions with respect to average sequence coverage of the
MTBC genome per fastq file. Each dot represents one isolate
(i.e. fastq file). Scanning time was found to be 112 seconds/100×
coverage. Eleven isolates of 880 were excluded due to variable read
lengths (difficult calculation of total base output). Three additional
isolates were excluded because of file sizes larger than 10 GB.
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sitions (single nucleotide positions plus regions of interest),
the BWA list of variants in the corresponding genome was
interrogated for presence of an alternative allele compared
to the reference genome (reconstructed hypothetical ances-
tor [38,41]). With this, a direct comparison of all 206 posi-
tions in 206 strains was performed, resulting in 42,436 data
points (Table 1).
A total of 782 mutations were called by both KvarQ and
the BWA-pipeline (1.8% of all data points). This corre-
sponds to a sensitivity of 99.2% in mutation calling of KvarQ
(782/788) taking the BWA pipeline as the gold standard.
Specificity was found to be 99.9% (41,615/41,648 positions).
Thirty-three mutations (0.08% of all data points) in 20
fastq files were called by KvarQ, but no mutation wasFigure 6 Phylogenetic classification of all 880 isolates used in this stu
the scanned genomes. For 865 isolates, an MTBC lineage-specific SNP was
because isolates were non-MTBC (10 were known to be non-MTBC), or becfound in the corresponding BWA SNP-list. Upon man-
ual inspection, we found a successful SNP-call in the
SAMtools pileup-list for each of the 33 mutations, but
these mutations were filtered out in the subsequent
heuristic filtering step including the SAMtools varFilter
command for unknown reasons and despite good quality
and coverage.
We found three fastq files where KvarQ missed a single
SNP and one file where KvarQ missed 3 SNPs despite six
calls in the BWA-pipeline. The BWA read depths for
these six calls (0.01% of all data points) were 5, 6, 21, 38,
64 and 77. Corresponding KvarQ number of hits were 0,
1, 2, 3, 4 and 5, respectively. For strain MTB_erd-
man_SRR017677, when the KvarQ quality cutoff was re-
moved (all reads considered), the number of hits
increased to 57, 84 and 120, respectively. Subsequent
FastQC analysis (http://www.bioinformatics.babraham.ac.
uk/projects/fastqc/) showed poor fastq quality over the
whole read length (data not shown).
Validation of phylogenetic classification
A subset of 321 isolates was used to compare the phylo-
genetic classification by KvarQ with data obtained previ-
ously by various genotyping methods (molecular assays in
our laboratory [40]), data obtained from the collaborating
laboratory that provided DNA for WGS, or metadata from
the sequence read archive in the case of downloaded files.
The comparison included seven main phylogenetic line-
ages [41], the animal-associated MTBC clade (M. bovis/M.
caprae), the Beijing sublineage of Lineage 2, and 10 non-
MTBC isolates. In 309/321 (96.3%) isolates, KvarQ
detected MTBC lineage-specific SNPs that were in agree-
ment with the previous classifications (Additional file 2).
The remaining 12 genome sequences for which no MTBC
lineage-specific SNP was found included eight non-
MTBC, the chimpanzee bacillus and M. canettii, fordy. This figure shows the distribution of phylogenetic markers in all of
found. In 15 isolates, no MTBC lineage-specific SNPs were found, either
ause coverage was low.
Table 1 Comparison of SNP-calls at 206 polymorphic
positions in 206 MTBC genome sequence fastq files
SNP in BWA mapping pipeline
Yes No Total
N % N % N %
SNP in KvarQ 782 99.24 33 0.08 815 1.92
no SNP in KvarQ 6 0.76 41615 99.92 41621 98.08
Total 788 100 41648 100 42436 100
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two isolates (0.6%) with low KvarQ coverage and therefore
no lineage-call.
Drug resistance associated mutations
KvarQ was applied to a subset of 19 strains harbouring
known mutations associated with drug resistance to valid-
ate the interpretation (annotation) of the mutations. The
19 strains overlapped with the 206 strains of the direct
comparison described above, but the resistance-associated
mutations were identified with separate scripts from the
annotated SNP-list in the BWA pipeline. The 179 drug re-
sistance associated genomic positions were interrogated
with KvarQ, including the 81 bp Rifampicin Resistance
Determining Region (RRDR) of rpoB, the 63 bp Quinolone
Resistance Determining Region of gyrA (QRDR) and 3 bp
in the codon 315 of katG (Additional file 1).
Among the 19 strains, 16 (84%) had perfectly congruent
drug resistance mutations identified by KvarQ when com-
pared to the BWA pipeline. For one strain (GQ1580), one
mutation in rpoC was not found by KvarQ. However, this
mutation was not in the list of target SNPs (Additional
file 1). For one isolate, MTB_KZN_605, an additional mu-
tation in gyrA was found with KvarQ, and was not found
with the BWA pipeline due to low read depth and the
presence of an alternative allele. For another isolate,
MTB_russia_ERR015616_1, six additional mutations in
five genes were found by KvarQ. All mutations in these
two isolates were traced back to the filtering problem dis-
cussed above, and were found in the pileup file.
In total, KvarQ detected 314 drug resistance associated
mutations in 139/880 files (15.8%) (Figure 7).
“Blind” set of fastq files from a public repository
Finally, a “blind” set of whole genome sequences was used
to illustrate the added value provided by KvarQ. We
downloaded available sequences of a recent publication
that used whole genome sequencing for molecular epi-
demiology of MTBC transmission [21]. This publication
did not report drug resistance data or phylogenetic data.
We therefore analyzed all available sequences for phylo-
genetic SNPs and drug resistance mutations. The original
sample set consisted of 390 isolates, but two fastq files
were not found for download (http://www.sanger.ac.uk,ERR192249 and ERR192250). Results for 388 isolates were
obtained in less than 12 hours. A total of 62 drug resist-
ance mutations were identified in 33 patient isolates from
11 patients (Figure 8). All paired isolates (cross-sectional:
paired pulmonary and extrapulmonary isolates from the
same patients; longitudinal: paired isolates from the same
patient separated by at least 6 months; shown as smaller
dotted boxes in Figure 8) were found to harbour identical
drug resistance associated mutations, except for one pa-
tient (P000155), where an additional mutation was found
in two of three isolates. Isolates of one community trans-
mission cluster (defined by MIRU-VNTR), cluster 9, were
found to harbour drug resistance associated mutations
(large box in Figure 8). Within cluster 9, all patient isolates
harboured the same drug resistance mutations, except for
one patient (P000179) with three otherwise unidentified
mutations. Among the 388 isolates, we found a predomin-
ance of Lineage 4 (i.e. the Euro-American lineage) in the
sample set (65.5%), followed by Lineage 3 (24.0%) and
Lineage 1 (5.9%) (Figure 9).
Discussion
In this article, we propose a new approach to in silico
SNP-typing from whole-genome sequencing data. KvarQ
scans fastq short sequence reads directly for known poly-
morphisms instead of mapping or assembling the
complete genome. This results in a massively reduced
computation time required compared to established WGS
analysis tools. At the same time, KvarQ offers a high de-
gree of flexibility and is also user-friendly. This was
achieved by developing an extended command-line inter-
face together with pre-compiled packages with a graphical
user interface.
KvarQ was designed for bacterial genomes, but is applic-
able to any fastq sequence data. The default parameters
work best for the different Illumina machines, but can eas-
ily be adapted to data from other manufacturers. For
example, the Roche 454 reads in our testset were scanned
with a lower quality cutoff. Due to the lack of relevant
data from MTBC isolates, we were not able to test reads
from Pacific Bioscience devices.
Both the reference sequence and the interrogated poly-
morphisms can be changed or extended. Changing the
SNPs of interest can be achieved by modifying the tem-
plates in the testsuites, which are lists of nucleotide posi-
tions screened by KvarQ. An extended documentation
including instructions for changing the target polymor-
phisms is distributed with the software and available on-
line (http://www.swisstph.ch/kvarq). Scanning parameters
are adjusted by invoking a number of options in the
command-line interface or via the settings dialog in the
graphical user interface.
Using our test set of 880 fastq files, we obtained KvarQ
running times of less than 2 minutes on a high-
Figure 7 MTBC drug resistance associated mutations found in all 880 isolates. This figure shows all 314 mutations that were found with
KvarQ in 139 isolates with at least one mutation in any of the drug resistance associated genes that were analysed (see Additional file 1). Only
mutations that were found in at least ten isolates are labeled.
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onds) and less than 20 minutes on a standard desktop
computer (Figure 5). This important decrease in time for
analysis (when compared to the conventional pipeline in
which the whole genome sequence is first reconstructed)
is crucial for the efficient treatment of data as WGS
becomes more widely available. The overall performance
of KvarQ was high, as reflected by 98.3% of genome
sequences successfully assigned to a phylogenetic MTBC
lineage (Figure 6). By including phylogenetically redundant
SNPs, the sensitivity of classification was increased. Specific-
ally, classifications were obtained if 2 of 3 redundant SNPsFigure 8 KvarQ identified 62 drug resistance associated mutations in
from Walker et al. [21]. Each circle represents one isolate (Patient numbe
drug resistance associated mutation identified by KvarQ are shown. The 62
Phylogenetic lineages were obtained with KvarQ and are shown as colored
publication [21]: cross-sectional isolates were paired pulmonary and extrap
paired isolates from the same patient separated by at least 6 months, and ge
the community. Paired isolates (longitudinal and cross-sectional) as well as iso
P000179, where three otherwise not detected mutations were found by KvarQ
two of three isolates. Two of the 390 whole genome sequences in the originawere found mutant. The 96.3% congruence of lineage-
assignment of KvarQ with a priori lineage classification illus-
trates how WGS combined with a quick tool such as KvarQ
has the potential to replace previous genotyping methods.
When comparing KvarQ SNP-calls with calls from our
mapping pipeline using BWA and SAMtools, we found a
high sensitivity and specificity of 99.2% and 99.9%, respect-
ively. The three mutations that were called by the BWA
pipeline but not by KvarQ were resolved when lowering the
quality cutoff parameter. FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/) confirmed the low quality
of the reads in these files.33 of 388 patient isolates in a “blind” set of genome sequences
r given as P-number, isolate given as ERR-number). Only isolates with
individual drug resistance mutations are shown as colors of pies.
and dashed boxes. Group definitions were obtained from the original
ulmonary isolates from the same patient, longitudinal isolates were
nomic cluster 9 was a large MIRU-VNTR defined cluster of transmission in
lates of cluster 9 were found to harbour the same mutations, except for
. For patient P000155, an additionally acquired mutation was found in
l publication were not found for download.
Figure 9 Main MTBC phylogenetic lineage classification of the fastq set of Walker et al. [21], consisting of 388 isolates. Successful
lineage assignment was obtained for 388/388 (100%) isolates. Figure includes all clustered isolates as well as longitudinal, cross-sectional and
household isolates.
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BWA in the 19 compared files were nearly identical, but
showed one limitation. Mutations conferring resistance
to pyrazinamide are found in any part of pncA, which is
561 bp long [44]. KvarQ was designed to scan short
stretches of DNA, and we therefore excluded mutations
in pncA to avoid an increase in scanning time.
In the total set of 880 genomes, we found many add-
itional drug resistance associated mutations (Figure 7) that
could not be validated due to the lack of laboratory DST
data for many of the isolates and the complex genetic na-
ture of drug resistance in MTBC [45].
Successful KvarQ calls depended on the selection of
suitable SNPs. Several SNPs had to be replaced in the
testing phase. Most SNPs that were replaced occurred in
repetitive regions, and these SNPs were also never called
when using the BWA-pipeline. We therefore recom-
mend including only SNPs that were previously found to
be in core genome regions, in non-repetitive regions and
where no deletions have been described.
With a “blind” set of genome sequences obtained from
a recent publication [21], we were able to obtain lineage
classifications and drug resistance calls, which had not
been reported in the original publication, in less than
one day. Using the clustering information of the publica-
tion, all isolates identified as drug-resistant by KvarQ
and from the same patient (paired isolates) or the same
patient cluster shared the same drug resistance muta-
tions (except patient P000179, see Figure 8) and were
assigned to the same phylogenetic lineage, highlighting
the consistency in mutation calling. The fast generation
of drug resistance and phylogenetic data illustrates the
application of KvarQ for quick targeted scanning of large
public datasets.
KvarQ was designed to interrogate positions with
known mutations. However, as some regions (e.g. hot spotregions of drug resistance) can harbour several mutations
in close proximity, we included the capability to scan re-
gions of interest for the presence of any (new) mutation.
These regions can be of any length, but the scanning time
increases in square with sequence length. The drug resist-
ance testsuite in the current version checks some short
regions known to harbour many different drug resistance
associated mutations and reports any new mutation that
would result in a amino acid change of the associated
gene. In future releases, KvarQ could be extended to scan
for other genomic polymorphisms, such as small inser-
tions and deletions (InDels) as well as large sequence dele-
tions or duplications.
Conclusion
In conclusion, KvarQ provides a user-friendly and highly
flexible platform for rapid and targeted analysis of fastq
files. KvarQ will help overcome the hurdles of whole
genome sequence analysis in clinical microbiological
laboratories and other settings where bioinformatics
capacity is limited. The short running times, the user-
friendly graphical interface and the high configurability
at the command line level allows analysing hundreds of
fastq files in a short time.
Methods
Informative SNPs for MTBC
We used known phylogenetic markers and drug resistance
associated mutations of MTBC to validate and benchmark
KvarQ when scanning genome sequences of clinical
MTBC strains. Phylogenetically informative SNPs were se-
lected from previous publications [40,42]. For each of the
seven main phylogenetic lineages of human-associated
MTBC, plus the Mycobacterium bovis/M. caprae lineage,
we included three redundant canonical SNPs as markers
for the corresponding lineage. Previously published SNPs
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fore [40] for cases where less than three SNPs per phylo-
genetic clade were available. The extraction of these
additional SNPs was based on 172 genomes described by
[41]. For Lineage 2, we additionally included known poly-
morphisms to discriminate the so-called “Beijing” lineage
from non-Beijing Lineage 2 strains. An overview of the
phylogenetically informative SNPs included in KvarQ is
shown in Additional file 1. We included drug resistance-
mutations obtained from the Tuberculosis Drug Resistance
Database (TBDReaMDB) [46], and additionally compensa-
tory mutations from [47]. High-confidence mutations for
the most important anti-tuberculosis drugs were selected
(isoniazid, rifampicin, ethambutol, streptomycin, fluoroqui-
nolones and second-line injectable drugs). Pyrazinamide-
resistance conferring mutations were excluded. Mutations
in TBDReamDB are listed as codon changes, therefore we
generated the corresponding nucleotide changes for inclu-
sion in KvarQ. For rifampicin- and fluoroquinolone-
resistance conferring mutations, we included the rifampi-
cin-resistance determining region (RRDR) [34] and the
quinolone resistance determining region (QRDR) [48],
respectively, rather than specific positions. The codon 315
of katG was also treated as a region of three base pairs. All
included mutations and regions associated with drug resist-
ance mutations are listed in Additional file 1. All genomic
positions given in this study refer to the genome of the
strain H37Rv (NC000962.3/AL123456.3) [44,49,50].
Short-read datasets
We used a test set of 880 bacterial whole genome se-
quences in fastq format to screen for mutations with
KvarQ. This set represents a global and diverse collection
of clinical isolates of MTBC, and includes drug-resistant
strains from patients and from in vitro evolution experi-
ments, as well as non-MTBC bacterial genome sequences.
Additionally, the genome sequences were chosen to repre-
sent a technically diverse collection (Illumina HiSeq 2000,
GAIIx and MiSeq). In addition to the genome sequences
generated in-house, the test set contains fastq files down-
loaded from www.sanger.ac.uk, the European Nucleotide
Archive (ENA; http://www.ebi.ac.uk/ena/) and the Se-
quence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/
sra). More information on the fastq files, including acces-
sion numbers, can be found in Additional file 2.
Mapping data for comparison with KvarQ
To compare KvarQ SNP calls with SNP calls obtained
from conventional mapping of fastq short sequencing
reads to a reference, we used a previously published
computational pipeline [43]. In brief, all short reads were
mapped to a hypothetical reconstructed ancestor with
BWA, reads were piled up with SAMtools and variants
called with BCFtools [51]. Filtering for low quality callswas done with customized scripts. The 206 positions
that were used in KvarQ for allele detection were ex-
tracted with a Python script and compared to the KvarQ
calls in the corresponding sequence. Discrepant results
were manually checked with Artemis [52].
KvarQ parameters used
All KvarQ results were generated using default parameters,
i.e. a quality cutoff of 13, a minimum read length of 25, a
minimum overlap of 25, a minimum coverage of two reads
for allele calls and a maximum of two errors per read.
Parameters were adjusted for fastq files with low coverage
or low quality values, and are reported in Additional file 2.
In case of paired-end sequencing files, only one of two read
files was used. Files were manually concatenated in case of
low coverage (reported in Additional file 2).
Hardware specification
KvarQ runs on any system that runs Python and has a
POSIX threads implementation (this includes notably
Windows, OS X and Linux). Analyses in this study were
performed on a Red Hat Enterprise Linux Server release
5.9 (Tikanga) with four six-core AMD Opteron CPUs
and 132 GB RAM, using 8 threads.
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